HighTower Advisors
ENTX icon

HighTower Advisors’s Entera Bio ENTX Stock Holding History

HighTower Advisors’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133K Buy
74,573
+37,743
+102% +$47.2K ﹤0.01% 3615
2026
Q1 		$40.9K Sell
36,830
-6,310
-15% -$8.86K ﹤0.01% 3723
2025
Q4 		$83.7K Buy
43,140
+25,000
+138% +$58.6K ﹤0.01% 3527
2025
Q3 		$34.8K Sell
18,140
-49,404
-73% -$94.5K ﹤0.01% 3637
2025
Q2 		$128K Buy
67,544
+49,404
+272% +$97.7K ﹤0.01% 3418
2025
Q1 		$30.8K Buy
18,140
+6,310
+53% +$13.7K ﹤0.01% 3489
2024
Q4 		$25.1K Hold
11,830
– – ﹤0.01% 3525
2024
Q3 		$22K Hold
11,830
– – ﹤0.01% 3503
2024
Q2 		$22K Hold
11,830
– – ﹤0.01% 3389
2024
Q1 		$20K Hold
11,830
– – ﹤0.01% 3350
2023
Q4 		$7K Hold
11,830
– – ﹤0.01% 3458
2023
Q3 		$9K Hold
11,830
– – ﹤0.01% 3391
2023
Q2 		$10K Buy
+11,830
New +$10.1K ﹤0.01% 3305

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

HighTower Advisors's ENTX Position: Q2 2026 in Review

HighTower Advisors increased its Entera Bio (ENTX) stake by 102% in Q2 2026, buying an estimated $47.2K and bringing the position to 74,573 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #3615.

HighTower Advisors first reported a position in ENTX in Q2 2023 and has held it in 13 quarters since. 27 funds tracked by Wall St. Rank hold ENTX as of Q2 2026.

  • HighTower Advisors held 74,573 shares of Entera Bio worth $133K as of Q2 2026.
  • HighTower Advisors bought 37,743 Entera Bio shares in Q2 2026, an estimated $47.2K.
  • Entera Bio made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3615 holding.
  • HighTower Advisors first reported a position in Entera Bio in Q2 2023 and has held it in 13 quarters since.
  • 27 funds tracked by Wall St. Rank held Entera Bio as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.